Firebrick Pharma

Firebrick Pharma EBITDA per Share

The EBITDA per Share of Firebrick Pharma (FRE.AX) as of Nov 17, 2026 is -0.01 AUD. In the previous year, EBITDA per Share was -0.01 AUD — a change of 0.57% (lower).

EBITDA per Share

-0.01AUD

YoY

0.57%

Last updated:

EBITDA per Share of Firebrick Pharma is 2026 -0.01 AUD. EBITDA per Share of Firebrick Pharma was 2025 -0.01 AUD. It decreases by 0.57% lower compared to the previous year.

The Firebrick Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-0.00 AUD
Jan 1, 2020
-0.01 AUD
Jan 1, 2021
-0.02 AUD
Jan 1, 2022
-0.02 AUD
Jan 1, 2023
-0.04 AUD
Jan 1, 2024
-0.02 AUD
Jan 1, 2025
-0.01 AUD
Jan 1, 2026
-0.01 AUD
The Firebrick Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
-0.01AUD+0.57%
-0.01AUD-39.60%
-0.02AUD-49.98%
-0.04AUD+73.60%
-0.02AUD+32.11%
-0.02AUD+42.52%
-0.01AUD+166.32%
-0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Firebrick Pharma Stock analysis

What does Firebrick Pharma do? Firebrick Pharma Ltd develops and commercializes Nasodine, a nasal spray treatment for the common cold based on povidone-iodine as an antimicrobial agent. The company owns patents covering intranasal povidone-iodine for cold treatment and prevention, pandemic viral disease prevention including COVID-19, and the Nasodine formulation. It is completing a Phase 2 trial for Nasodine in COVID-19 and a Phase 3 trial to confirm efficacy for the common cold, aiming to secure regulatory approvals and international partnerships. The company makes money through the development and commercialization of Nasodine, targeting markets requiring regulatory approvals and partnerships. Its patents and clinical trials support market entry in regions seeking effective cold treatments and pandemic prevention solutions. The Phase 3 trial results are critical for securing international approvals and partnerships, which drive revenue from product sales and licensing agreements. Firebrick Pharma Ltd's revenue streams are derived from the commercialization of Nasodine, with key focus on securing regulatory approvals and forming partnerships in markets where the common cold and pandemic prevention are priorities. The company's patent portfolio and clinical trial progress are central to attracting partners and enabling market entry for Nasodine. Firebrick Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Firebrick Pharma stock

EBITDA per Share of Firebrick Pharma is -0.01 AUD in 2026.

EBITDA per Share of Firebrick Pharma changed from -0.01 AUD to -0.01 AUD, representing a 0.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Firebrick Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Firebrick Pharma

All Key Metrics — Firebrick Pharma